Human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) are promising
candidates to treat myocardial infarction and other cardiac diseases. Such treatments …

Rationale: Ventricular arrhythmias remain the leading cause of death in patients suffering
myocardial ischemia. Myeloperoxidase, a heme enzyme released by polymorphonuclear …

Introduction: The potentially unlimited number of cardiomyocyte (CMs) derived from human
induced pluripotent stem cells (hiPSCs) in vitro facilitates high throughput applications like …

Abstract Background/Aims: Common systems for the quantification of cellular contraction
rely on animal-based models, complex experimental setups or indirect approaches. The …

Cardiomyocytes, differentiated from induced pluripotent stem cells (iPSCs), have the
potential to produce patient-and disease-specific pharmacological and toxicological …

Adult cardiomyocytes (CMs) possess a highly restricted intrinsic regenerative potential—a
major barrier to the effective treatment of a range of chronic degenerative cardiac disorders …

Gingival stem cells (GSCs) are a novel source of mesenchymal stem cells (MSCs) that are
easily accessed from the oral cavity. GSCs were considered valuable autograft MSCs with …

Ischemia reperfusion (I/R) injury, an inevitable event accompanying heart transplantation, is
the primary factor leading to organ failure and graft rejection. In order to prevent I/R injury …

MicroRNAs (miRNAs) are small (18–25 nucleotides), noncoding RNAs that have been
identified as potential regulators of bone marrow stromal cell (BMSC) proliferation …

Background/Aims: To investigate whether nucleosome assembly protein 1-like 1 (Nap1l1)
regulates the proliferation of induced pluripotent stem cells (iPSC) and the potential …